Lupus

First and foremost, I want to remind you that this is an editorial, which by definition offers an “opinion,” so I don’t want to be pilloried for overstating data or brandishing irrational enthusiasm.

It is not often that a single data set has the potential to fundamentally alter the treatment landscape for a disease in rheumatology, but recent findings on the use of chimeric antigen receptor T-cells in lupus may eventually do just that.

Following last year’s U.S. Supreme Court’s decision overturning federal abortion protections, rheumatologists must change their practice with regard managing patients’ reproductive health, said presenter at the 2023 AWIR annual conference.

Rheumatologists can help patients with lupus and other rheumatic diseases avoid potentially dangerous unintended pregnancies by regularly documenting their contraception use, according to a presenter at the 2023 AWIR annual conference.

The overwhelming majority of rheumatology practices have no formal policy for transitioning pediatric patients to adult care, according to a presenter at the 2023 AWIR annual conference.

Patients with multiple diseases that share immunologic pathways may benefit from therapies that target those shared pathways, but additional studies are needed in this area, according to a presenter at the 2023 AWIR annual conference.

Blood dendritic cell antigen 2 and neonatal fragment crystallizable receptor are two novel strategies in lupus that may play a larger role in the future, according to a presenter at the 2023 AWIR annual conference.

AUSTIN, Texas — Although reproductive health represents a unique challenge in patients with lupus, success is possible with careful planning and consideration, said a presenter at the 2023 Rheumatology Nurses Society annual conference.

Patients with systemic lupus erythematosus demonstrate a higher risk for ischemia heart disease, with the biggest danger manifesting 6 to 9 years after diagnosis, according to data published in BMC Rheumatology.